Experimental and Prescriptions of Chinese Medicine
The mechanism of the combination of radix ophiopogonis and schisandra chinensis on atherosclerosis based on network pharmacology
Lyu Yanni, Fu Longsheng, Qian Yisong, Wen Jinhua, Wei Xiaohua, Zhou Jian, Li Yuhua
Published 2020-02-28
Cite as Int J Trad Chin Med, 2020,42(02): 144-150. DOI: 10.3760/cma.j.issn.1673-4246.2020.02.010
Abstract
ObjectiveTo excavate the mechanism of the combination of Radix Ophiopogonis and Schisandra chinensis to treatatherosclerosisbased on network pharmacology to discuss its mechnism.
MethodsThis paper excavated the associated proteins with Radix Ophiopogonis and Schisandra chinensis from the TCMGeneDIT database, and constructed the multicomponent protein network of Radix Ophiopogonis, Schisandra chinensis and proteins ApoE-/- mice were randomly divided into control group, model group, low, medium, high dose group and atorvastatin calcium group. Except the control group, other groups were fed with H10540 high fat diet for 12 weeks. From the 4th week, the atrovastatin calcium group was given atrovastatin calcium liquid 6 mg/kg by gavage. The low, medium and high dose groups were administed 4.68, 2.34 and 1.17 g/kg, respectively, once a day by gavage for 8 weeks. The oil red staining was applied to observe the pathological changes of atherosclerotic aortic wall. Western blot was subjected to detect the expression change of mitogen activated protein kinases p38 (p38), ATP binding cassette subfamily G member 1 (ABCG1), Toll like receptor 4 (TLR4), heat shock protein 90 alpha family class a member 1 (HSP90AA1), MMP-9 and arachidonate 5-lipoxygenase (ALOX5) in liver tissue, as well as nuclear factor related factor 2 (Nrf2) and heme oxygenase 1 (HO-1) in brain tissue.
ResultsIt was found that eleven components were interacted with 37 proteins, forming a protein interaction network with 48 nodes and 190 boundaries without isolated nodes. Compared to the model group, the level of p-p38/p38 (2.12 ± 0.12, 1.76 ± 0.11, 1.69 ± 0.10 vs. 2.45 ± 0.16), TLR4 (1.98 ± 0.10, 1.64 ± 0.11, 1.55 ± 0.12 vs. 2.68 ± 0.06), HSP90AA1 (1.79 ± 0.10, 1.66 ± 0.09, 1.59 ± 0.11 vs. 2.06 ± 0.07), MMP9 (1.84 ± 0.11, 1.75 ± 0.12, 1.66 ± 0.08 vs. 2.68 ± 0.10) in liver tissue of low, medium and high dose groups significantly decreased, the level of ABCG1 (0.53 ± 0.08, 0.78 ± 0.09, 0.81 ± 0.10 vs. 0.45 ± 0.04), ALOX5 (0.59 ± 0.04, 0.67 ± 0.09, 0.88 ± 0.07 vs. 0.47 ± 0.02) in liver tissue of low, medium and high dose groups significantly increased (P<0.05). The expression of Nrf2 (1.62 ± 0.12, 1.32 ± 0.09, 1.14 ± 0.06 vs. 2.12 ± 0.08) in cytoplasm of brain tissue significantly decreased, and Nrf2 (1.12 ± 0.09, 1.61 ± 0.07, 1.68 ± 0.11 vs. 1.07 ± 0.08) in cell nucleus of brain tissue significantly increased. The expression of HO-1 (1.16 ± 0.09, 1.73 ± 0.11, 1.82 ± 0.08 vs. 1.05 ± 0.04) in brain tissue significantly increased.
ConclusionsNetwork pharmacology and molecular biology were used to elucidate the molecular mechanism of the combination of Schisandra chinensis and Ophiopogon japonicus in the prevention and treatment of atherosclerosis, also to validate the related mechanism via Nrf2 pathway, which provided a reference for the further study of the combined prescription.
Key words:
Ophiopogonis radix; Schisandrae chinensis fructus; Atherosclerosis; Network pharmacology; Molecular mechanisms of pharmacological action (TCD)
Contributor Information
Lyu Yanni
Department of Pharmacy, the First Affiliated Hospital of Nanchang University, Nanchang 330006, China
Fu Longsheng
Department of Pharmacy, the First Affiliated Hospital of Nanchang University, Nanchang 330006, China
Qian Yisong
Cardiovascular Disease Research Center, Institute of Translational Medicine, Nanchang University, Nanchang 330001, China
Wen Jinhua
Department of Pharmacy, the First Affiliated Hospital of Nanchang University, Nanchang 330006, China
Wei Xiaohua
Department of Pharmacy, the First Affiliated Hospital of Nanchang University, Nanchang 330006, China
Zhou Jian
Department of Pharmacy, the First Affiliated Hospital of Nanchang University, Nanchang 330006, China
Li Yuhua
Department of Pharmacy, the First Affiliated Hospital of Nanchang University, Nanchang 330006, China